1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag

Medix to submit final version of tesofensine application following interaction with COFEPRIS

MAR

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner Medix sees a clear regulatory path forward for tesofensine following discussions with the Mexican regulatory agency COFEPRIS.

Since the message from COFEPRIS, communicated in Saniona’s press releases of November 6 and November 12, 2024, Productos Medix S.A. de S.V. (Medix) has worked closely with COFEPRIS on the approval pathway for tesofensine in Mexico. Following these discussions, Medix now sees a clear path to regulatory approval and is revising its application based on COFEPRIS’s feedback. Medix expects to resubmit the dossier in February.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline includes SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona’s most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-10 08:00 CET.

Attachments
Medix to submit final version of tesofensine application following interaction with COFEPRIS

Datum 2025-02-10, kl 08:00
Källa MFN
Bifogade filer
Medix to submit final version of tesofensine application following interaction with COFEPRIS
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.